X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Where will all the FDI go? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jan 22, 2009

    Where will all the FDI go?

    FDI to decline in emerging markets
    With the financial crisis deepening in 2008, emerging markets which were believed to be decoupled from the developed world were in for a rude shock, as Foreign Institutional Investors (FIIs) relentlessly dumped stocks in these countries causing the stock markets to plunge. But it appears that foreign direct investment (FDI) is also most likely to follow suit. As per Bloomberg, FDI in developing nations will drop by US$ 180 bn, or 31% this year as global recession compels multinationals to cut spending on factories and mines. FDI fell an estimated 10% in the developing world in 2008.

    Companies such as Rio Tinto, Honda and Hitachi Construction have either shelved their expansion plans or delayed the same in markets such as Brazil, India, China, Argentina and Turkey. As reported on Bloomberg, according to World Bank estimates, FDI in developing countries is expected to shrink to US$ 400 bn this year from an estimated US$ 580 bn in 2008 and US$ 500 bn in 2007. Besides global trade contracting this year for the first time since 1982, pressure is also expected to mount on the currencies of these nations. Just like the developed world, emerging nations are in for some tough times indeed in 2009.

    China's growth slows, Japan's exports plunge
    Bloomberg reports that China's GDP (gross domestic product) growth slowed down to 6.8% during the October-December 2008 quarter. This is the slowest pace of growth for the country in a span of seven years, and is largely a result of sharp slowdown in exports to the US and Europe. Economists now predict the country's growth to weaken to 3% to 4% during the current quarter, before stimulus measures kick in and export demand starts to revive.

    China is not the only major Asian nation to feel the pressure of a slowing global demand. It has Japan as company. Asia's largest economy has recorded a 35% YoY decline in exports during December 2008. This signals that Japanese companies will now be forced to cutback on production and downsize employees, thereby driving the economy deeper into recession. This decline in exports is the largest the country has faced since 1980.

    In the meanwhile, while stocks in China are trading marginally in the positive, Japanese markets are trading weak currently. The US markets closed strong yesterday led by strong earning report from the technology major IBM. The Dow Jones Industrial Index closed 3.5% up.

    Dr. Reddy's German angst
    Indian pharma major, Dr. Reddy's made headlines in 2006 when it acquired the German company Betapharm for US$ 570 m, which was touted as the largest acquisition made by an Indian pharma company. At that time, because Germany was a branded generics market, revenue and profit growth expectations from this company were high as it was the fourth largest player in Germany with products at the higher end of the value chain. But then the tide turned since then.

    Problems began with Germany opting to intensify efforts to make healthcare more affordable as a result of which the government made it mandatory that there be a certain differential between the price of the branded drug and the patented one. This led Betapharm to undertake price cuts across its product basket, consequently impacting its revenues and profits.

    Then the company began to face supply constraints when its key supplier Salutas failed to meet production schedules. Of course, this problem was resolved by shifting the manufacturing to India. But the main problem of pricing pressure continues to persist. Moreover, the market has now shifted towards a tender based model wherein insurance companies have a larger say in the prescription of the drugs. Therefore margins will be on the lower side with volumes being the key driver.

    To add fuel to the fire, the company had to withdraw the drug 'Olanzapine' from the market as the German court ruled in favour of the innovator. The management of Dr. Reddy's remains hopeful that things will improve going forward. But the way things stand now, what began as a huge promise seems to have turned into a damp squib.

     

     

    Equitymaster requests your view! Post a comment on "Where will all the FDI go?". Click here!

      
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    You've Heard of Timeless Books... Ever Heard of Timeless Stocks? (The 5 Minute Wrapup)

    Aug 19, 2017

    Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 18, 2017 (Close)

    MARKET STATS